<DOC>
	<DOCNO>NCT00276497</DOCNO>
	<brief_summary>A three year prospective , double blind , placebo control , randomize clinical trial impair glucose tolerance ( IGT ) subject study effect pioglitazone prevent conversion Diabetes .</brief_summary>
	<brief_title>Role Pioglitazone Preventing Diabetes</brief_title>
	<detailed_description>A randomize control study design find whether pioglitazone prevent conversion diabetes subject non obese impair glucose tolerance . It double blind prospective study 3 year . The study start October 2003 randomization complete May 2005 . A total 6643 subject screen 406 randomize either pioglitazone placebo ( investigator blinded-groups assign A B ) . At randomisation subject give standard advice diet , exercise benefit life style modification . Subjects male female , age 35 55 year , know history diabetes , willing available 3 year study alone screen . Pregnant woman , subject major illness cancer , hepatic cardiac disease transferable job exclude study . The initial dose tablet 15mg o.d . titrate month 30 mg o.d . subject show adverse event . The subject undergoing annual review repeat OGTT , 3 year . An interim review every six month also do . Proforma contain detail anthropometry , occupation , physical activity , dietary habit , detail medication , regularity treatment do interview . The main expect outcome study reduction conversion IGT diabetes benefit drug anthropometric variable biochemical parameter .</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Both male female Age 35 55 year No known history diabetes Willing available 3 year study Pregnant woman Subjects major illness cancer , hepatic cardiac disease Transferable job</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Impaired glucose tolerance</keyword>
	<keyword>Intervention</keyword>
	<keyword>Prevention</keyword>
</DOC>